Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP-005 Vaccine Alone or with Toripalimab in MRD+ AML
NCT06980155Phase 1Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- May 2025
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of XP-005 in acute myeloid leukemia (AML) (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started May 2025; status: recruiting.
02
Drugs
XP-005
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06980155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980155.